Pharmacy Times

JULY 8, 2022

Findings suggest that the HER2 L755S mutation plays a role in the aggressiveness of lobular breast cancer observed in the clinic.

139

139

European Pharmaceutical Review

JULY 4, 2022

Ensuring potential microbial contaminants are not transferred into cleanroom environments is a key aspect of risk mitigation strategies. In a review, pharmaceutical microbiologist and contamination control expert Tim Sandle, reviewed several methods of material transfer, listing the decontamination methods based on efficacy and commenting on their weaknesses. .

134

134

pharmaphorum

JULY 8, 2022

The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and development efforts, and its spend in this area has created a multibillion-dollar market for AI technologies. That’s the conclusion of a GlobalData report , which notes that AI is being used to enhance computer-aided drug design (CADD) in a bid to reduce the time and costs involved in getting a new drug to market.

Compounding 131

Compounding 131

Pharmaceutical Technology

JULY 6, 2022

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7. Elsewhere, San Diego, California-based Heron Therapeutics announced restructuring and layoffs for 34% of its workforce.

129

129

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

JULY 8, 2022

David Pope, PharmD, CDE, the EVP of Innovation and Industry Relations at OmniSYS, discusses the FDA’s announcement updating pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid.

FDA 132

FDA 132

European Pharmaceutical Review

JULY 8, 2022

As established facilities age, various risk considerations emerge. While some may continue to function effectively without any additional considerations, many will require additional checks and assessment. In an article published in the Journal of Validation Technology (JVT), pharmaceutical microbiologist and contamination control expert Tim Sandle identified ten categories of risk presented by aging.

128

128

Pharmaceutical Technology

JULY 4, 2022

GlaxoSmithKline (GSK) has completed the acquisition of all outstanding shares of US-based Sierra Oncology in a deal totalling $1.9bn (£1.6bn), in cash. In April this year, GSK entered an agreement for the acquisition of Sierra Oncology for $55 per share. The conclusion of the deal comes after the shareholders of Sierra Oncology approved the takeover on 29 June this year.

Vaccines 122

Vaccines 122

Pharmacy Times

JULY 7, 2022

People have been taking probiotics to support digestive health for centuries, but researchers in the pulmonary field have turned their attention toward how microbiome science can be used to support the lungs.

132

132

European Pharmaceutical Review

JULY 5, 2022

After more than 20 years of environmental action, Pfizer has committed to further reduce its greenhouse gas (GHG) emissions and aims to achieve the voluntary Net-Zero Standard by 2040 – a full 10 years ahead of the standard’s proposed timeline. To achieve these goals, Pfizer aims to decrease its GHG emissions by 95 percent and its value chain emissions by 90 percent from 2019 levels by 2040.

Pharmaceutical Companies 111

Pharmaceutical Companies Pharmaceutical Companies Hospitals 111

pharmaphorum

JULY 5, 2022

Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a global health initiative launched by the company last year. The medicines – which include insulin, oral diabetes agent glibenclamide and cancer chemotherapy oxaliplatin – will be sold under a new Impact brand and are all classed as essential medicines by the World Health Organisation (WHO).

Chemotherapy 119

Chemotherapy Vaccines 119

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. Following the option exercise, Vir will receive the option exercise fee, regulatory and commercial milestone payments as well as tiered royalties on net product sales from Brii Bio.

111

111

Pharmacy Times

JULY 8, 2022

Simple changes to each day can improve motivation and wellness for pharmacists.

131

131

PharmaVoice

JULY 7, 2022

Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.

105

105

pharmaphorum

JULY 4, 2022

GSK’s recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has moved closer to fruition, now that the first partners have joined the initiative. The asset management arm of Swiss back UBS has formed a joint venture with property developer Reef Group that will develop the 33-acre campus in Stevenage, Hertfordshire.

119

119

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

JULY 7, 2022

Brii Biosciences and TSB Therapeutics have commercially launched a long-acting neutralising antibody therapy combination, amubarvimab/romlusevimab, for Covid-19 in China. The two non-competing SARS-CoV-2 monoclonal neutralising antibodies, amubarvimab and romlusevimab are obtained from convalesced Covid-19 patients. The company developed these antibodies in partnership with Tsinghua University and the 3rd People’s Hospital of Shenzhen.

Hospitals 105

Hospitals 105

Pharmacy Times

JULY 3, 2022

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

FDA 131

FDA 131

European Pharmaceutical Review

JULY 5, 2022

The Impact ® brand includes 30 Sanofi medicines and covers a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer. Medicines include insulin, glibenclamide and oxaliplatin, the company said. Sanofi has also established an Impact fund to support startup companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. .

Vaccines 105

Vaccines 105

pharmaphorum

JULY 5, 2022

Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. With more than 500 dermatology clinical trials currently underway, it is often heard that there is a ‘’competition for participants’’. Yet evidence from research studies and a survey with 4,000+ atopic dermatitis patients conducted by Clariness shows that this ‘race to recruit’ is actually not the primary reason for the growing discontinuation rate of atopic dermatitis trials.

Communication 118

Communication 118

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

JULY 6, 2022

The European Commission (EC) has granted approval for the expanded conditional marketing authorization (CMA) of Novavax’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), in the European Union (EU) for adolescents of the age 12 to 17 years. A protein-based vaccine, NVX-CoV2373 is made from the genetic sequence of the SARS-CoV-2 virus’ first strain. The latest development comes after the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive recommendation in

Vaccines 105

Vaccines Adverse Reactions 105

Pharmacy Times

JULY 7, 2022

Trauma informed care has had an impact on the public health spectrum for years, especially with what has happened on a global front.

130

130

PharmaVoice

JULY 6, 2022

Ratings agency Moody’s lays out the risk exposure for industry leaders.

104

104

pharmaphorum

JULY 5, 2022

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. The two partners will take an in vivo approach to the problem of so-called sensorineural hearing loss (SNHL) looking at ways to replace sound-detecting hair cells in the inner ear (cochlea) that become damaged in this type of deafness.

110

110

European Pharmaceutical Review

JULY 5, 2022

Stomach cancer, also known as gastric cancer, is the fifth most common type of cancer worldwide – and the third most common cause of death from cancer. 1 Approximately half of all cases occur in eastern Asia, but thanks to more advanced screening programmes in countries like Japan, survival rates in these regions are improving compared with western countries.

Chemotherapy 104

Chemotherapy Dosage Labelling Compounding 104

Pharmacy Times

JULY 8, 2022

Autologous stem cell transplantation was underutilized in community settings for mantle cell lymphoma.

123

123

Pharmaceutical Commerce

JULY 8, 2022

How did the industry get here and what alternatives can be sought out?

98

98

pharmaphorum

JULY 7, 2022

Pfizer is still waiting for the green light to complete an acquisition of digital health company ResApp, a deal that looks even better now that its smartphone app for people with obstructive sleep apnoea (OSA) has been approved by the FDA. Brisbane, Australia-based ResApp has claimed a 510(k) clearance for SleepCheckRx as a prescription-only digital therapy in the software-as-a-medical device (SaMD) category, clearing the path for a commercial launch in the US.

FDA 105

FDA 105

PharmExec

JULY 8, 2022

Continent has shed its ‘emerging’ status on world biopharma stage.

98

98

Pharmacy Times

JULY 8, 2022

Hypervitaminosis D, a condition characterized by elevated vitamin D levels, is associated with potential serious health issues, such as psychosis, abdominal pain, vomiting, pancreatitis, and renal failure.

123

123

PharmaVoice

JULY 7, 2022

Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

98

98

pharmaphorum

JULY 5, 2022

Cancer drugs will be flown from a facility in Portsmouth to a hospital on the Isle of Wight by drone, in the first pilot study of the technology by NHS England. The trial – announced this morning and said to be the first of its type worldwide – will mean that the lifesaving treatment can be picked up and dropped off to patients on the same day, said NHS chief executive Amanda Pritchard.

Chemotherapy 105

Chemotherapy Hospitals 105

European Pharmaceutical Review

JULY 7, 2022

Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. He will be based out of Teva’s US headquarters in Parsippany, New Jersey. . “Eric brings nearly 20 years of leadership roles with a proven track record in a variety of R&D functions for global pharmaceutical companies, and has a successful record of accomplishment fostering productive collaborations with

Research Laboratories 98

Research Laboratories Pharmaceutical Companies Pharmaceutical Companies Hospitals 98

Pharmacy Times

JULY 8, 2022

ProAir Digihaler Inhalation Powder is indicated for the treatment or prevention of bronchospasm in those with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

123

123

PharmaVoice

JULY 6, 2022

From M&Ms to biotech, the chief financial officer's sweet tooth for taking risks is paying off.

98

98